CAR T-Cell Therapy Market

The CAR T-cell therapy market is projected to reach USD 13.78 billion in 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7% during the forecast period. The growth of the CAR T-cell therapy market is propelled by the growing prevalence of cancer and technological advancements in the CAR T-cell therapy market. Additionally, rising investment and funding for CAR T-cell therapy development are further likely to drive the market.

The global CAR T-cell therapy market is consolidated with top players such as Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), CARsgen Therapeutics Holdings Limited (China),  IASO Biotherapeutics (China), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), CRISPR Therapeutics (Switzerland), Autolus Therapeutics (UK), Allogene Therapeutics (US), Cartesian Therapeutics, Inc. (US), Guangzhou Bio-gene Technology Co., Ltd (China), and Wugen (US). Market players have adopted various strategies, including new product launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions, to strengthen their positions in the global CAR T-cell therapy market.  

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US)

Thermo Fisher is a leading global proteomics player with a strong end-to-end workflow footprint. Its Orbitrap mass spectrometers, LC systems, and automated sample prep solutions are widely used across pharma, CROs, and academic centers, globally. The company also strengthens downstream workflows through data analysis and informatics that support large cohort and multiomics programs. With the addition of next-generation proteomics platforms to its broader life science portfolio, Thermo is positioning itself as a single vendor partner for scalable discovery and translational proteomics across North America, Europe, and Asia Pacific.

Bristol-Myers Squibb Company (US)

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering and developing therapies across oncology, hematology, immunology, cardiovascular disease, and neuroscience. It is one of the leading players in the CAR T-cell therapy market, supported by strong brand equity and a robust product portfolio. The company continues to invest heavily in R&D to advance new therapeutic innovations and sustain its leadership position.

Gilead Sciences, Inc. (US)

Gilead Sciences is a research-driven biotechnology company engaged in the discovery, development, and commercialization of innovative medicines. The company markets two US FDA-approved CAR T-cell therapies, Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel). Gilead’s acquisition of Kite Pharma and the subsequent commercialization of Yescarta established a strong footprint in the CAR-T space. Ongoing collaborations with academic institutions, biotech companies, and healthcare providers further strengthen its R&D and clinical capabilities by enabling access to novel technologies and accelerating clinical development. For example, in November 2023, Arcellx and Gilead expanded their collaboration for Arcellx’s CAR-T program targeting multiple myeloma.

Novartis AG (Switzerland)

Novartis AG is a healthcare company that develops novel therapies across cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. The company’s products are significant contributors to the CAR T-cell therapy market. Novartis gained an early foothold in the CAR T-cell therapy market with the FDA approval of Kymriah (tisagenlecleucel) in 2017, becoming the first approved CAR T-cell therapy for B-cell precursor Acute Lymphoblastic Leukemia (ALL). This approval enabled Novartis to establish strong brand recognition and credibility in the field. The company also has a strong geographic presence with distribution channels across North America, Europe, Asia Pacific, Latin America, and Africa.

Related Reports:

CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com